Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Tries Out New Selling Strategy With Yervoy Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Company details "new customer model" with an integrated reimbursement and medical support team that is being rolled out for the ipilimumab launch.
Advertisement

Related Content

Yervoy Off to Strong Start, Says BMS' Tony Hooper
Yervoy Off to Strong Start, Says BMS' Tony Hooper
As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Bristol Basks In Broad Ipilimumab Label, Sets High Price
Bristol Basks In Broad Ipilimumab Label, Sets High Price

Topics

Advertisement
UsernamePublicRestriction

Register

PS072165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel